profit from every $100 of sales.
$0$100
Rallybio
$15.72+0.45% today
+199.4% in 1 year
1-year low $4.331-year high $17.22
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2024 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Rallybio sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $858,000 in 2025, with -$8.98 million of profit last year.
SalesProfit
Rallybio vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Rallybio | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Rallybio's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 1 | 1 | |
| – | – | – | – | |
| -68 | -79 | -60 | -33 | |
| -68 | -79 | -60 | -33 | |
| -67 | -75 | -58 | -9 | |
| -16.72 | -14.72 | -10.64 | -1.59 | |
| – | – | – | – | |
| – | – | -9,511.9% | -3,853.6% | |
| – | – | -9,084.1% | -1,046.4% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 180 | 116 | 68 | 62 |
| Cash | 57 | 24 | 14 | 31 |
| Total debt | 1 | 0 | 0 | 0 |
| Total liabilities | 11 | 9 | 6 | 4 |
| 169 | 106 | 62 | 58 | |
| 4 | 5 | 5 | 6 | |
| -31.6% | -58.5% | -77.3% | -44.9% | |
| -39.4% | -70.2% | -93.7% | -15.5% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -57 | -60 | -49 | -30 | |
| 0 | 0 | – | – | |
| -57 | -60 | -49 | -30 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 9 | 11 | 8 | 5 |
Valuation
- –
- –
- –
- 1.3×
- 102.6×
- –
- –
- -33.9%
- -10.2%
- 0.0%
Profitability
- 99.7%
- -3,853.6%
- -1,046.4%
- -3,842.9%
- -56.9%
- -49.0%
- -16.2%
- -14.4%
- -57.0%
- 2,283.7%
Growth
- +34.9%
- –
- +39.5%
- –
- +8.8%
Financial health
- -0.9×
- 0.00
- 0.3%
- –
- 14.50
- 14.50
- 0.01
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 5%of 952
Top 15%of 886
Bottom 2%of 987
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 13, 2026 | -1.46 | -1.20 | −21.7% |
| Mar 12, 2026 | -1.28 | -1.24 | −3.2% |
| Nov 6, 2025 | -0.14 | -0.25 | +44.0% |
| Aug 7, 2025 | -0.22 | -0.20 | −12.8% |
| May 8, 2025 | -0.21 | -0.21 | +0.0% |
| Mar 13, 2025 | -0.25 | -0.27 | +7.4% |
| Nov 7, 2024 | -0.26 | -0.36 | +27.8% |
| Aug 8, 2024 | -0.37 | -0.42 | +11.9% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
2/7Passes 2 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
39No pass
Benjamin Graham
65Pass
Philip Fisher
57No pass
Peter Lynch
100Pass
Joel Greenblatt
2No pass
Charlie Munger
52No pass
Terry Smith
55No pass
Questions about Rallybio
Is Rallybio a good stock to buy?
A business with weak numbers that is not profitable yet. 2 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Rallybio AI analysis
What does Rallybio do?
Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. It is in Biotechnology.
Does Rallybio pay a dividend?
No. Rallybio does not pay a dividend at the moment.
Is Rallybio stock halal?
No. Rallybio does not pass our halal screen: its cash and confirmed interest-bearing investments are 36% of its market value, at or above the 33% limit. How we check
How has Rallybio stock done over the past year?
Up 199.4% over the past twelve months, to $15.72. It traded between $4.33 and $17.22 and is 8.7% below its high.
Who are Rallybio's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Rallybio's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.